Author

Shom Goel

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Atirmociclib and fulvestrant for patients with HR+/HER2- advanced/metastatic breast cancer who progressed on a prior cyclin-dependent kinase 4/6 inhibitor: primary analysis of the randomized FourLight-1 trial.

BACKGROUND Atirmociclib is a potential first-in-class, highly selective cyclin-dependent kinase (CDK) 4 inhibitor, demonstrating significantly greater selectivity over CDK6. In a phase 1/2a study, atirmociclib plus endocrine therapy was well tolerated and showed encouraging antitumor activity in patients with HR+/HER2-...

A. Giordano, B. Xu, T. Yoshinami et al. · Annals of Oncology · 0 citations

Open access Aug 2026

Rb-driven transcription limits its tumour-suppressive effects in breast cancer

The retinoblastoma protein (Rb) is a tumour suppressor best known for repressing E2F transcription factors and halting cell cycle progression1. In hormone receptor-positive (HR+) breast cancer, CDK4/6 inhibitors activate Rb by preventing its phosphorylation, forming a key component of current endocrine therapy regimens...

April C. Watt, Antonio Ahn, Catherine Blyth et al. · Nature · 2 citations

Open access Aug 2026

Closing the fusion-detection gap in single-cell RNA-seq with a scalable, probe-based workflow

Single-cell RNA-sequencing resolves cellular states in exquisite detail. Yet oncogenic gene fusions, key drivers in 16.5% of malignancies and ∼50-70% of acute lymphoblastic leukaemia (ALL) cases, remain largely invisible at this resolution. This leaves a fundamental gap in understanding cancer biology. We close it with...

Jovana Maksimovic, Victoria Streeton-Cook, Calandra V. Grima et al. · bioRxiv · 0 citations